<p>This is a study to determine the efficacy of androgen receptor (AR) inhibitors in LAR (luminal androgen receptor)-enriched triple-negative breast cancer (TNBC) in the neoadjuvant setting. Twenty-four patients were treated with neoadjuvant AR inhibitor enzalutamide and paclitaxel for 12 weeks. Whole exome sequencing and RNA-sequencing was performed prior to treatment. The data for only two patients are consented for release through dbGaP. The remaining data are available under a Materials Transfer Agreement with the University of Texas MD Anderson Cancer Center.<br></p>

Luminal Androgen Receptor-Enriched Triple Negative Breast Cancer

15 variables across Demographics, Disease Events

Luminal Androgen Receptor-Enriched Triple Negative Breast Cancer

Demographics (1)

Disease Events (1)

Other (13)